Özet:

Aim: The aim of this study is to compare the demographic, clinical, laboratory characteristics and mortality rates of malignant patients followed in the COVID-19 and non-COVID-19 intensive care units (ICU) during the pandemic. Material and Methods: This is a retrospective observational study that included patients with oncological diagnosis of COVID-19 and non-COVID-19 hospitalized in the ICU between March 23, 2020 - January 31, 2022. Adult patients (≥18 years), with hematological or solid organ malignancy were included in this study. Patients were divided into two groups; first group admitted to ICU with the diagnosis of COVID-19 (polymerase chain reaction (PCR) test positive) and second gropu admitted to ICU without the diagnosis of COVID-19 (PCR test negative and clinically and radiologically confirmed that they were not COVID-19). Data of two groups were compared. Results: A total of 283 patients, 150 of whom had malignancies with COVID-19, and 133 patients with malignancies with non-COVID-19 were included in the study. When the malignancy characteristics of the two groups were compared; cured malignancy was significantly higher in the COVID-19 group. The rates of patients with solid organ malignancies were statistically higher in the COVID-19 group (85.3%), while those with hematological malignancies (24.1%) were statistically higher in the non-COVID-19 group (p=0.04 and 0.03, respectively). In addition, lung carcinoma (22%) was statistically significantly higher in the COVID-19 group. Predictors of mortality were invasive mechanical ventilator (IMV) requirement, duration of IMV, concomitant neurologic disease and need of vasopressor/inotrope. Conclusion: It was concluded that the mortality rate in COVID-19 malignant patients was lower than that of non-COVID-19 malignant patients, and that requirement and duration of IMV, the need of vasopessor/inotrope, and concomitant neurological disease were effective in mortality in all malignant patients. We think that the higher mortality in the nonCOVID-19 patient group may be due to factors such as end stage of the malignancy, clinical course, and immunosuppressive treatment (radiotherapy, chemotherapy, etc.).